Catalog No.
KVV24301
Description
PRINCIPLE OF THE ASSAY
This assay employs the quantitative sandwich enzyme immunoassay technique. An antibody specific for MARV Envelope glycoprotein has been pre-coated onto a microplate. Standards or samples are pipetted into the wells and any MARV Envelope glycoprotein present is bound by the immobilized antibody. After washing away any unbound substances, a biotin-labeled antibody specific for MARV Envelope glycoprotein is added to the wells. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of MARV Envelope glycoprotein bound in the initial step. The color development is stopped and the intensity of the color is measured.
Applications
Used for the quantitative determination of MARV Envelope glycoprotein concentration in serum and plasma.
Specificity
Lake Victoria marburgvirus (MARV) Envelope glycoprotein (GP)
Detection method
Colorimetric
Sample type
Plasma, Serum
Assay type
Quantitative
Range
26.34 - 300 ng/mL
Sensitivity
15.36 ng/mL
Precision
Intra-Assay Precision (Precision within an assay): <10%
Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): <15%
Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.
|
|
Intra-Assay Precision
|
Inter-Assay Precision
|
|
Sample
|
1
|
2
|
3
|
1
|
2
|
3
|
|
n
|
16
|
16
|
16
|
24
|
24
|
24
|
|
Mean (ng/mL)
|
173.5
|
82.3
|
35.6
|
184.5
|
85.0
|
34.5
|
|
Standard deviation
|
7.6
|
5.7
|
5.0
|
7.1
|
4.9
|
2.2
|
|
CV (%)
|
4.4
|
7.0
|
14.1
|
3.9
|
5.7
|
6.5
|
Recovery
80-120%
Shipping
2-8 ℃
Stability and Storage
When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.
Note
For Research Use Only.
A Cloned Recombinant Vesicular Stomatitis Virus-Vectored Marburg Vaccine, PHV01, Protects Guinea Pigs from Lethal Marburg Virus Disease., PMID:35891170
Mining of Marburg Virus Proteome for Designing an Epitope-Based Vaccine., PMID:35911751
Marburg Virus VP30 Is Required for Transcription Initiation at the Glycoprotein Gene., PMID:35997284
Ligand-based design of peptide entry inhibitors targeting the endosomal receptor binding site of filoviruses., PMID:36007601
Assays for the Evaluation of the Immune Response to Marburg and Ebola Sudan Vaccination-Filovirus Animal Nonclinical Group Anti-Marburg Virus Glycoprotein Immunoglobulin G Enzyme-Linked Immunosorbent Assay and a Pseudovirion Neutralization Assay., PMID:36016099
Protection against Marburg Virus and Sudan Virus in NHP by an Adenovector-Based Trivalent Vaccine Regimen Is Correlated to Humoral Immune Response Levels., PMID:36016151
Immune Correlates of Protection from Filovirus Efficacy Studies in Non-Human Primates., PMID:36016226
First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study., PMID:36197845
Nonhuman Primates Are Protected against Marburg Virus Disease by Vaccination with a Vesicular Stomatitis Virus Vector-Based Vaccine Prepared under Conditions to Allow Advancement to Human Clinical Trials., PMID:36298451
Single-Shot ChAd3-MARV Vaccine in Modified Formulation Buffer Shows 100% Protection of NHPs., PMID:36423030
A rabies virus-vectored vaccine expressing two copies of the Marburg virus glycoprotein gene induced neutralizing antibodies against Marburg virus in humanized mice., PMID:36453198
Ebola Virus Activates IRE1α-Dependent XBP1u Splicing., PMID:36680162
Chaperoning the driver of filovirus egress to a dead end., PMID:36763514
Rapid protection of nonhuman primates against Marburg virus disease using a single low-dose VSV-based vaccine., PMID:36774693
Pseudotyped Viruses for Marburgvirus and Ebolavirus., PMID:36920694
Computational Modeling and Evaluation of Potential mRNA and Peptide-Based Vaccine against Marburg Virus (MARV) to Provide Immune Protection against Hemorrhagic Fever., PMID:37101690
Structural and Energetic Basis for Differential Binding of Ebola and Marburg Virus Glycoproteins to a Bat-Derived Niemann-Pick C1 Protein., PMID:37119290
A Highly Attenuated Panfilovirus VesiculoVax Vaccine Rapidly Protects Nonhuman Primates Against Marburg Virus and 3 Species of Ebola Virus., PMID:37171813
The Inability of Marburg Virus to Cause Disease in Ferrets Is Not Solely Linked to the Virus Glycoprotein., PMID:37288605
Preexisting Immunity Does Not Prevent Efficacy of Vesicular Stomatitis Virus-Based Filovirus Vaccines in Nonhuman Primates., PMID:37290042
Long-term Prophylaxis Against Aerosolized Marburg Virus in Nonhuman Primates With an Afucosylated Monoclonal Antibody., PMID:37474248
Immunoinformatic and reverse vaccinology-based designing of potent multi-epitope vaccine against Marburgvirus targeting the glycoprotein., PMID:37534001
Contrasting effects of filamin A and B proteins in modulating filovirus entry., PMID:37585478
Transcriptional profiling of immune responses in NHPs after low-dose, VSV-based vaccination against Marburg virus., PMID:37616377
Designing a novel and combinatorial multi-antigenic epitope-based vaccine "MarVax" against Marburg virus-a reverse vaccinology and immunoinformatics approach., PMID:38012426
Thermostable bivalent filovirus vaccine protects against severe and lethal Sudan ebolavirus and marburgvirus infection., PMID:38158300
Production and Purification of Filovirus Glycoproteins., PMID:38315357
A novel MARV glycoprotein-specific antibody with potentials of broad-spectrum neutralization to filovirus., PMID:38526940
Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine., PMID:38543955
Divergent antibody recognition profiles are generated by protective mRNA vaccines against Marburg and Ravn viruses., PMID:38585993
(+)-fenchol and (-)-isopinocampheol derivatives targeting the entry process of filoviruses., PMID:38889610
A Microsphere Immunoassay for the Quantitative Detection of Antigens in Cell Culture Supernatant., PMID:38951344
Design of a novel multi-epitope vaccine against Marburg virus using immunoinformatics studies., PMID:38970027
Vaccine Platform Comparison: Protective Efficacy against Lethal Marburg Virus Challenge in the Hamster Model., PMID:39126087
Rational design of self-amplifying virus-like vesicles with Ebola virus glycoprotein as vaccines., PMID:39217415
Longitudinal proteome-wide antibody profiling in Marburg virus survivors identifies wing domain immunogen for vaccine design., PMID:39285186
Lysosome-Associated Membrane Protein Targeting Strategy Improved Immunogenicity of Glycoprotein-Based DNA Vaccine for Marburg Virus., PMID:39340043
Generation, Recovery, and Propagation of a Recombinant Vesicular Stomatitis Virus Expressing the Marburg Virus Glycoprotein., PMID:39585614
In Vivo Investigation of Filovirus Glycoprotein-Mediated Infection in a BSL2 Setting., PMID:39585622
Quantification of Neutralizing Antibodies in Serum Using VSV-MARV-GFP., PMID:39585633
Serological Evidence of Potential Marburg Virus Circulation in Livestock and Dogs in Ghana., PMID:39599470
Construction and evaluation of glycoprotein-based nucleic acid vaccines for Marburg virus., PMID:39607590
A surrogate BSL2-compliant infection model recapitulating key aspects of human Marburg virus disease., PMID:39745141
Rapid Development of Modified Vaccinia Virus Ankara (MVA)-Based Vaccine Candidates Against Marburg Virus Suitable for Clinical Use in Humans., PMID:39771978
From protein to immunology: comprehensive insights into Marburg virus vaccines, mechanism, and application., PMID:40025302
Jamaican fruit bats' competence for Ebola but not Marburg virus is driven by intrinsic differences., PMID:40133326
MyosinVb tail inhibits transport of Marburg virus glycoprotein GP to VP40-enriched sites at the plasma membrane., PMID:40174331
Molecular virulence determinants of human-pathogenic filoviruses., PMID:40379380
Process Intensification for Recombinant Marburg Virus Glycoprotein Production Using Drosophila S2 Cells., PMID:40391203
Potent neutralization of Marburg virus by a vaccine-elicited monoclonal antibody., PMID:40463027
For research use only. Not for human or drug use.
